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The neurologic manifestations of HIV include a spectrum of HIV associated 
neurocognitive disorders (HAND), as well as a cluster of neurologic symptoms and 
signs. The neurological manifestations have been modified but not eradicated by 
antiretroviral therapy (ART). We describe the neurological phenotype in South 
African black HAND patients with predominant HIV-1 subtype C infection on ART 




We conducted a cross-sectional analyses of the neurological examination findings of 
HIV+ patients with neurocognitive impairment and used multiple linear regression to 
explore associations with neurocognitive impairment, efavirenz and 8-hydroxy-
efavirenz pharmacokinetics (plasma and CSF). 
 
Results 
We included 80 participants established on ART (median 40 months), 72 (90%) 
were female, aged 35 (32 – 42) years, median [interquartile-range (IQR)], with a 
median GDS 0.94 (IQR 0.63-1.36). We found statistical significant associations with 
neurocognitive impairment and neurological signs: gait [slow walking speed (p=0.03; 
R2=0.06), gait ataxia (p<0.01; R2=0.21), abnormal gait appearance (p<0.01; 
R2=0.18)]; coordination [upper extremity bradykinesia (p<0.01; R2=0.10) and lower 
extremity bradykinesia (p=0.01; R2=0.10)]; reflexes [jaw jerk (p=0.04; R2=0.05), 
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palmo-mental response (p=0.03; R2=0.06)]; ocular signs [smooth pursuit (p=0.01; 
R2=0.09), saccades (p<0.01; R2=0.15)] and motor signs [spasticity (p=<0.01; 
R2=0.15), muscle weakness (p=0.01; R2=0.08)]. No significant associations were 
found between plasma and cerebrospinal efavirenz or 8-hydroxy efavirenz 
concentrations and any neurological sign. 
 
Conclusion 
We found that individual neurological signs were associated with neurocognitive 
impairment in South African black HIV+ patients with predominant HIV-1 subtype C 












Mild forms of HIV-associated neurocognitive disorder (HAND) remain prevalent in 
antiretroviral experienced patients (up to 45%).1 HAND is diagnosed using 
neuropsychological testing with patients performance below 1 standard deviation 
from the norm in at least 2 cognitive domains, however such detailed 
neuropsychological assessments are not always practical in the clinical setting.2,3 
Clinicians therefore rely on various screening tools, functional assessments and 
limited neuropsychological tests for diagnosis.2 Unfortunately, screening tools, 
including the International HIV dementia Scale, are limited in their ability to detect 
milder forms of HAND with a high false-negative rate.4 Currently, neurological signs 
are not included in HAND definitions3, although abnormalities in gait, coordination, 
frontal release signs as well as ocular signs (impaired smooth pursuit and saccades) 
have been associated with HAND in patients with predominately HIV-1 clade B 
infection.5–13 The inclusion of primitive reflexes in the case definition of HAND has 
been suggested.12 Moreover, HAND neurological manifestations have not been 
described in the clade C predominant HIV infected sub-Saharan Africa.5–13  Clade 
variances demonstrate different degrees of neuronal toxicity in vitro with reduced 
neuro-virulence of HIV clade C versus clade B, although supporting clinical data is 
lacking.14–17 Additionally, efavirenz and its metabolite 8-hydroxy-efavirenz may be an 
additional contributor to neurocognitive impairment.18–21 
 
Our primary objective is to describe the neurological phenotype in South African 
black HIV+ patients with neurocognitive impairment and with predominant HIV-1 
subtype C on ART. Our secondary objective was to assess the neurological 
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phenotype association with neurocognitive impairment and efavirenz and 8-hydroxy-
efavirenz concentrations (plasma and CSF). 
 
Methods 
Participants: We included adults (≥ 18 and ≤ 70 years) who were screened and/or 
participated in a RCT (PACTR201310000635418) investigating lithium as adjunctive 
therapy in patients with neurocognitive impairment.22 Participants were established 
on ART for at least 6 months prior to the study with suppressed viral loads (HIV 
PCR <400copies/mL). All participants gave written informed consent. The study was 
approved by the Stellenbosch University Health Research Ethics Committee 
(0578/2017) and University of Cape Town Human Research Ethics Committee 
(071/2013).  
Neurological assessment: Participants received a full neurological examination by 
medical practitioners who received additional training in the neurological evaluation. 
All neurological assessments were reviewed by a neuropsychiatrist. Each 
neurological sign and symptom was assessed according to a standardized 
neurological assessment and quantified based on a previously defined tool.23,24 The 
neurological examination included peripheral neuropathy (visual analogue scale, 
vibration perception and ankle reflexes), motor system (involuntary movement, 
muscle bulk, tone and power), gait (appearance, coordination , timed gait test), limb 
coordination, reflexes (deep tendon reflexes and the primitive reflexes snout, grasp, 
palmo-mental, glabellar tap and plantar response) neck stiffness, facial strength and 
ocular signs (saccades and smooth pursuit). A binary score was assigned to 
indicate absent and present neurological signs to allow for statistical analysis.23  
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Neuropsychiatric assessment: The Global Deficit Score (GDS), a summative 
neuropsychology test battery score adjusted for age, education, gender, and 
ethnicity, was calculated for each participant.25 The domains (tests utilized) were 
attention (Mental Alternation Test, Digit Span, Paced Auditory Serial Addition Test), 
learning and memory (the Hopkins Verbal Learning Test), motor speed (Finger 
Tapping Dominant Hand, Finger Tapping Non-Dominant Hand, Grooved Pegboard 
Test Dominant Hand, Grooved Pegboard. Test Non-Dominant Hand), psychomotor 
speed (Trail Making Test A, Color Trails Test 1, Digit Symbol-Coding), executive 
function (Color Trails Test 2, Stroop Color-Word Test, Wisconsin Card-Sorting Test), 
visual learning and memory (Rey Complex Figure), and verbal fluency (Animals and 
Fruit and Vegetables). Symptoms of depression were also screened for using the 
Center for Epidemiologic Studies Depression (CES-D) scale.  
Pharmacokinetic assessment: Forty-six participants consented to lumbar 
punctures. CSF microbiology studies were reported on 36 participants while 
efavirenz and 8-hydroxy-efavirenz pharmacokinetic data were available for all 46 
participants. 
Pharmacokinetic sampling: Paired plasma and CSF samples for efavirenz and its 
metabolites were collected. Participants recorded time of efavirenz dosing the night 
before and were admitted the following morning for pharmacokinetic sampling. Mid-
dosing lumbar punctures were performed. Whole blood was collected within 45 
minutes of CSF sampling, centrifuged within 1 hour of collection, aliquoted and 
stored at -80°C until analysis. CSF was aliquoted and stored at -80°C until analysis. 
Efavirenz and metabolites: Drug assays were performed at 2 laboratories. The 
analytical laboratory in the Division of Clinical Pharmacology at the University of 
Cape Town quantified total efavirenz in plasma and CSF using validated liquid 
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chromatography tandem mass spectrometry assays. The lower limit of quantification 
(LLOQ) for plasma efavirenz was 19.5 ng/ml.  For CSF the LLOQ for total efavirenz 
was 0.5 ng/ml. The Bioanalytical Facility, Department of Molecular and Clinical 
Pharmacology at the University of Liverpool quantified total CSF 8-hydroxy-
efavirenz and plasma 8-hydroxy-efavirenz and plasma using validated LC/MS-MS 
assays.26 The LLOQ for CSF 8-hydroxy-efavirenz and plasma 8-OH-EFV was 3.125 
ng/ml and 5.0 ng/ml respectively. Concentrations below the limit of quantification 
were analyzed as missing data.  
Statistical analysis: Categorical data was described using proportions and 
depending on the number of variables, Chi-square or Fisher exact tests were used 
in hypothesis testing where appropriate. Numerical data distribution was assessed 
for normality and data were further described using means and standard deviations 
or medians and interquartile ranges where appropriate. For the primary outcome, 
associations between GDS and the individual neurological signs and symptoms 
were determined using a linear regression model. A p-value of <0.05 was 
considered significant. The primary outcome was further explored using a 
multivariate linear regression model and variables with either poor variation and/or 
too few events were excluded from the model. A p-value of <0.05 was considered 
significant. Secondary outcomes explored associations between efavirenz and 8-
hydroxy-efavirenz plasma and CSF concentrations, and their respective 
plasma:CSF ratios with neurological signs and symptoms. Linear regression models 




Eighty participants were included in the study. All participants were black Africans, 
with the majority being both Xhosa speaking (n=73; 91%) and female (n=72; 90%). 
The median GDS was 0.94 (Interquartile range, IQR 0.63 – 1.36). The baseline 
characteristics are presented in Table 1. Many participants experienced symptoms, 
and had signs, suggestive of peripheral neuropathy (n=32, 40%). However, in linear 
regression analysis both subjective and objective peripheral neuropathy indicators 
were not found to be significantly associated with GDS (Table 2). A number of 
neurological signs were associated with GDS (Table 2). Statistical significant 
associations for motor signs were spasticity (p<0.01; r2=0.15) and muscle weakness 
(p=0.01; r2=0.08); abnormalities in gait in the form of slowed walking speed (p=0.03; 
r2=0.06), gait ataxia (p<0.01; r2=0.21) and abnormal gait appearance (p<0.01; 
r2=0.18); abnormalities in limb coordination in the form of upper extremity 
bradykinesia (p<0.01; r2=0.10) and lower extremity bradykinesia (p=0.01; r2=0.10); 
brisk deep tendon reflexes in the form of jaw jerk (p=0.04; r2=0.05); primitive 
reflexes in the form of palmo-mental reflex (p=0.03; r2=0.06); and lastly ocular signs 
including impaired smooth pursuits (p=0.01; r2=0.09) and impaired saccades 
(p<0.01; r2=0.15). All associations were found to be positive, except for the palmo-
mental response and snout reflex which had a negative association. When included 
in a multivariate linear regression model certain neurological signs and their 
association with GDS remained statistically significant (Table 3). Additional 
variables found to be associated with GDS, not established in univariate analysis, 
were vibration perception score as a measure of peripheral neuropathy (p<0.01), the 
grasp reflex (p=0.03) as well as gender (p=0.05). CSF parameters, which included 
CSF -cell count, -culture, -chemistry, -albumin and CSF: serum albumin ratios were 
normal (data not shown). We previously described the pharmacokinetics of 
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efavirenz and its metabolites in plasma and CSF.27 In summary, plasma efavirenz 
median (IQR) was 1960 (1390 – 3200) ng/ml, range 55 – 18100 ng/ml; CSF 
efavirenz median (IQR) 17.25 (10.7 – 19.9) ng/ml, range 1.73 – 119 ng/ml. Plasma 
8-hydroxy-efavirenz median (IQR) was 1808 (1325.5 – 2498.7) ng/ml, range 68.8 – 
4887.5 ng/ml and CSF 8-hydroxy-efavirenz median (IQR) 4.17 (3.80 – 5.79) ng/ml, 
range 3.15 – 9.56 ng/ml. We found no statistically significant associations between 
any of the neurological signs and symptoms and efavirenz or 8-hydroxy-efavirenz in 




To our knowledge this is the first study that examined the association between 
neurological signs and HAND severity in a black African population with a 
predominant clade C HIV-infection. We found that certain neurological signs are 
associated with more severe forms of HAND, especially abnormalities in gait 
(slowed walking speed, gait ataxia and abnormal gait appearance), coordination 
(bradykinesia of the lower and upper limbs), motor signs (spasticity, decreased 
muscle strength, hyperreflexia), reflexes (palmo-mental reflex) as well as ocular 
signs (impaired smooth pursuits and saccades). Multivariate analysis confirmed the 
association of motor signs (decreased muscle strength); abnormalities in gait 
(slowed walking sleep); primitive reflexes (palmo-mental reflex) and ocular signs 
(impaired smooth pursuits) with GDS. Neurological symptoms and signs were not 
associated with plasma or CSF efavirenz or 8-hydroxy-efavirenz concentrations. 
 
Our findings replicate that of others who associated abnormalities in gait, 
coordination (body bradykinesia, abnormalities in rapid alternating movement), 
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motor signs (spasticity, decreased muscle strength, hyperreflexia), frontal release 
signs and ocular signs (impaired smooth pursuits) with HAND.6,8–13,28,29 We found 
that the palmo-mental reflex had a negative association with the GDS which is 
counter intuitive. The neurological phenotype of HAND has been best described 
during the pre-ART era.6,8–10,12,28,29 The first description in 1986 described a wide 
range of deficits from mild weakness and coordination disturbances to seizures, 
incontinence and quadriparesis.5 Subsequent studies described abnormalities in 
rapid alternating movement, frontal release signs, extrapyramidal signs and 
abnormalities in eye movements demonstrating mostly abnormal smooth 
pursuits.6,8–10,12,29 Neurocognitive impairment in the post-ART era is associated with 
extrapyramidal signs and soft neurological signs described in the Heidelberg 
Scale.11,13 Neurological phenotype of HAND data is predominantly representative of 
a male HIV-1 clade B infected population with data lacking in females and HIV-1 
subtype C infected individuals.  Clade C is the most prevalent HIV-1 subtype of sub-
Saharan Africa and is predominant (89%) in our study setting (Cape Town).30 Our 
findings contribute to the growing body of clinical evidence that neuropathology is 
similar in both Clade C and B HIV-1 subtypes.16,17 South Africa sees a high 
proportion of women presenting for HIV care.31 HIV positive women have an 
increased susceptibility of cognitive impairment particularly in psychomotor speed, 
attention and motor skills while no sex differences were demonstrated in HIV 
negative participants.32,33 These differences reflect the proposed influences of 
‘sexual dimorphism on immune function, pathogenesis and antiretroviral 
pharmacokinetics’, but also differences in mental health prevalence and 
sociodemographic patterns between sexes.32,33 Our study population consisted of a 
predominant female population and we found similarities in the neurological 
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phenotype compared with a male predominant setting. However, appropriately 
powered studies designed to confirm this finding is required.  
 
Efavirenz is known to initially cause neuropsychiatric symptoms such as headache, 
dizziness, impaired concentration, abnormal dreams and anxiety.34,35 This is usually 
transient in nature and resolves over time. Efavirenz, along with its metabolite 8-
hydroxy-efavirenz, has been shown to be neurotoxic through a range of different 
mechanisms even at therapeutic concentrations.18,19,36 Patients starting efavirenz-
based ART rather than protease inhibitors or all-nucleoside reverse transcriptase 
inhibitor regimens had less improvement in neurocognitive function scores after 48 
weeks in a randomised controlled trial (RCT).37 Patients from the CNS HIV 
Antiretroviral Therapy Effects Research (CHARTER) cohort who received efavirenz 
performed worse in several cognitive domains compared with protease inhibitor 
users after more than a year of ART.21 A recent case series report of 20 participants 
describes efavirenz toxicity as a reversible clinical syndrome of ataxia and 
encephalopathy in underweight and presumed genetic slow metabolizers on long 
term- ART.38 Efavirenz and 8-hydroxy-efavirenz was therefore an important 
confounding factor to consider in our population. No patients in our study had 
efavirenz toxicity which may explain the lack of association between efavirenz and 
8-hydroxy-efavirenz with neurological signs.  
 
Our study has a number of limitations. First, the primary RCT on which our study is 
based was not originally designed to look at associations between neurological 
manifestations and the GDS.22 Second, the primary RCT included participants with 
moderate to severe neurocognitive impairment (GDS ≥ 0.5) and our distribution of 
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impairment was skewed, therefore limiting our ability to describe associations with 
milder forms of neurocognitive impairment. Third, our study was observational in 
nature and not appropriately powered to allow for an accurate multivariate linear 
regression model. Without matched HIV seronegative controls, the true predictive 
value of certain neurological signs and symptoms could not be reliably estimated. 
Fourth, examining doctors were only blinded to the degree of neurocognitive 
impairment and not to the participant’s HIV-status during neurological examination. 
For this reason, examination bias may have been introduced. Fifth, no measure of 
functional ability was assessed in this population. This limited our ability to reliably 
assess the effect of neurological signs on activities of daily living or to be able to 
define HAND stage. Last, it is possible that some of our findings are due to 
peripheral neuropathy rather than the central nervous system disease.  
 
Current guidelines include the addition of daily functioning impairment to its criteria 
when differentiating between symptomatic and asymptomatic neurocognitive 
impairment.3 The prevalence of asymptomatic neurocognitive impairment decreased 
from 76% to 59% when combining self-report and performance based approaches.39 
Self-reported activities of daily living is the most convenient method to assess daily 
functioning but may be influenced by self-report bias, depression and the severity of 
cognitive dysfunction and can therefore increase the risk for HAND false-positive 
errors.39,40 Neurological impairment could potentially be used as a tool to objectively 
assess certain aspects of daily function (i.e. coordination and gait) and can be used 
together with self-report to further delineate functional impairment. Further research 
is however needed to better define the neurological phenotype and its relationship to 
functional impairment.  Additionally, neurological signs could be used as a pragmatic 
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and easy to determine marker of neurocognitive decline, especially in a busy clinic 
setting where it could augment the clinical assessment of HAND especially when the 
availability of neuropsychological testing is limited. However, the true predictive 
value of the neurological phenotype for the severity of HAND needs to be 
determined. 
 
In summary, we found that certain neurological signs are associated with more 
severe forms of HAND, especially abnormalities in gait, coordination, motor signs, 
reflexes as well as ocular signs in South African black HAND patients with 
predominant HIV-1 subtype C on ART. Our findings do not suggest a difference in 
neurological phenotype between HIV clade C and B or between males and females. 
Neurological symptoms and signs were not associated with plasma or CSF 
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